中文

Madrigal (MDGL)

Biotech

Close on Nov 3, 2026 (from our latest article): $396.32

Market value
$9.2Bat the Nov 3 closeIncluding convertible preferred and pre-funded warrants: $11.6B
Revenue growth
+93%12 months to Sep 30, 2026 (10-Q)
FCF margin
−12%12 months to Sep 30, 2026 (10-Q)
Net cash
$620Mat Sep 30, 2026
Worst fall since listing
−98.4%Jan 28, 2013 to Feb 10, 2016; back to that high in Aug 2025

About the company

Latest

  • Down 8.1% Quarterly
    Madrigal Q3 2026: first profit and a sales beat, yet shares end 8% lower

The Long View

Madrigal’s filings show a development company that funded itself by selling shares, preferred stock and pre-funded warrants, then won US accelerated approval for Rezdiffra in March 2024 and EU conditional approval in August 2025.

▲ better · ▼ worse · ⚠ watch, latest quarter · share count · cash

Updated Nov 3, 2026

Read the Long View →

Our View Opinion

Madrigal has the first and best-selling MASH drug and has just reported its first profitable quarter, but it is still a one-drug company whose approvals rest on outcomes trials still to report.

Median value, end-2030
$860P10–P90 $487–$1,525
Chance of beating the hurdle
84%
Implied end-2030 multiple
5.4× 2031 salesP25–P75 4.1–7.3× · today 5.3×

Biggest risk: The worst realistic case is a failed F4c trial in 2027 followed by rivals and rising rebates; the tail risk is a failed confirmatory trial in 2028 that puts the approval itself in question.

Nov 3, 2026 · our analysis, not investment advice UPDATED NOV 4

Read Our View →

Long-term fundamentals

Annual results for Madrigal, FY2009–FY2025, as reported in its 10-K filings.

Revenue and free cash flow

Revenue went from $0.1M in FY2012 to $958M in FY2025. Free cash flow was positive in 0 of the 17 years shown; FY2025: −$190M. Each year's figures are in the table below. −$500M$0$500M$1B ’09 ’11 ’13 ’15 ’17 ’19 ’21 ’23 ’25

Revenue went from $0.1M in FY2012 to $958M in FY2025.

Free cash flow was positive in 0 of the 17 years shown; FY2025: −$190M.

Margins

Operating margin was −31% in FY2025, vs −276% in FY2024. Each year's figures are in the table below. −50000%−40000%−30000%−20000%−10000%0% ’12’24’25

Operating margin was −31% in FY2025, vs −276% in FY2024.

Diluted share count

The diluted share count rose 45% from FY2020 to FY2025, to 22M. Each year's figures are in the table below. 10M20M30M40M50M ’09’10’11’20’21’22’23’24’25

The diluted share count rose 45% from FY2020 to FY2025, to 22M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025$958M—−31%−$288M−$190M$0.5M−$190M
FY2024$180M—−276%−$466M−$456M$1M−$457M
FY2023$0——−$374M−$324M$1M−$326M
FY2022$0——−$295M−$225M$0.2M−$225M
FY2021$0——−$242M−$184M$0.2M−$184M
FY2020$0——−$202M−$158M$0.3M−$158M
FY2019$0——−$84M−$42M$0.2M−$42M
FY2018$0——−$33M−$26M$0.0M−$26M
FY2017$0——−$31M−$22M$0.1M−$22M
FY2016———−$26M−$18M$0.0M−$18M
FY2015————−$3M$0.1M−$3M
FY2014————−$79M$0.1M−$79M
FY2013————−$77M$0.8M−$78M
FY2012$0.1M—−41456%—−$54M$0.5M−$55M
FY2011————−$47M$0.7M−$48M
FY2010————−$38M$0.1M−$38M
FY2009————−$27M$0.5M−$27M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY202522M$984M$340M$98M——
FY202421M$926M$118M$80M——
FY202319M$634M$115M$50M——
FY202217M$359M$70M$32M——
FY202117M$270M$0$27M——
FY202015M$284M—$21M——
FY2019—$439M—$23M——
FY2018—$484M—$13M——
FY2017—$192M—$3M——
FY2016—$19M—$8M——
FY2015—$0.3M—$4M——
FY2014—$0.1M$14M$7M——
FY2013—$48M$23M$6M——
FY2012—$82M$4M$3M—$0.0M
FY201147M$30M$12M$3M——
FY201040M$31M$12M$4M——
FY200934M$44M—$5M——

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 3, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

Returns by year

YearMDGLS&P 500
2019−19.2%+31.5%
2020+22.0%+18.4%
2021−23.8%+28.7%
2022+242.5%−18.1%
2023−20.3%+26.3%
2024+33.4%+25.0%
2025+88.7%+17.9%
2026 to date−31.9%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Biotech

Show all 17

Questions about Madrigal

How does Madrigal make money?
Madrigal sells one medicine, Rezdiffra (resmetirom), a once-daily pill for MASH, a fatty-liver disease that scars the liver. In 2025 all $958.4M of its revenue was Rezdiffra net product revenue, and it pays Roche, which discovered the molecule, a tiered single-digit royalty on net sales. More in the Long View →
What are Madrigal's main growth levers?
More patients on Rezdiffra (more than 55,850 at Sep 30, 2026), its EU approval in August 2025, a second Phase 3 trial in compensated cirrhosis, and MASH drug candidates licensed since mid-2025 for use in combination with Rezdiffra. More in the Long View →
Why are Rezdiffra's approvals conditional?
Its US approval (March 2024) and EU approval (August 2025) are both conditional on outcomes data that confirm the clinical benefit, from Madrigal's MAESTRO-NASH trial. Rezdiffra is approved for adults with moderate to advanced liver scarring, but not cirrhosis. More in the Long View →
How dependent is Madrigal on a few partners?
Five unnamed specialty pharmacies and distributors took 90% of its gross product revenue in the first nine months of 2026 together (our calculation). It also relies on outside manufacturers: Evonik for the active ingredient, and UPM and Corden for tablets. More in the Long View →
What creates Madrigal's funding risk?
Rezdiffra sales provide cash, but licensing upfronts, receivables and inventory also consume it. Madrigal has funded pipeline licences with cash and carries a secured term loan. More in the Long View →

Disclosure: one or more of our editors own shares of Madrigal (MDGL) as a long-term investment.